Progenity Inc Aktie News
0,59 $
19,44 %
Nasdaq,
Fr, 24.05.2024
tracken
Progenity Inc Aktie News
Neutral
GlobeNewsWire
●
etwa 2 Jahre alt
Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy
Neutral
GlobeNewsWire
●
etwa 2 Jahre alt
Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms
Neutral
GlobeNewsWire
●
etwa 2 Jahre alt
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is a...
Neutral
Seeking Alpha
●
etwa 2 Jahre alt
Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
Positiv
PennyStocks
●
etwa 2 Jahre alt
Will these penny stocks be on your watchlist in April? The post Should You Invest in These Penny Stocks Next Month?
Neutral
GlobeNewsWire
●
etwa 2 Jahre alt
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will ...
Neutral
GlobeNewsWire
●
etwa 2 Jahre alt
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world's premier meeting for physicians, research...
Neutral
GlobeNewsWire
●
mehr als 2 Jahre alt
Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
